FDA’s National Center for Toxicological Research is latest site of SOMAscan assay

FDA’s National Center for Toxicological Research is latest site of SOMAscan assay

12/14/2015

SomaLogic announced today that the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) has reached an agreement with SomaLogic to deploy the SOMAscan proteomics assay in the NCTR’s research laboratories in Jefferson, Ark. It is expected that the assay will be installed and fully functional at NCTR by early 2016.

Founded in 1971, NCTR’s mission is to “develop and support innovative tools and evaluation of approaches that FDA uses to protect and promote individual and public health.” More than 500 scientists work at NCTR, which also hosts students, postdoctoral fellows, visiting scientists and FDA staff who go to NCTR to learn new laboratory technologies.

“We are delighted to partner with the FDA’s National Center for Toxicology Research to give its extensive network of researchers access to the SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “The deployment of this cutting-edge proteomics tool in the NCTR laboratories will contribute greatly to their efforts to fufill their important national mission.”

Compared to other current proteomic technologies, SomaLogic’s platform offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, can efficiently, accurately and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

The FDA’s NCTR is the ninth leading research center announced to date that has brought the SOMAscan assay “in house” to accelerate its scientific efforts. SomaLogic is continuing to expand research access to the SOMAscan assay through placements at additional centers over the next several months.

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

12/7/2015

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics*, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis (RA) in a cynomolgus monkey model of the disease. The SOMAmer molecule used in these studies, named SL1026, was initially selected for its ability to directly bind and block the signaling of the critical inflammatory protein interleukin-6 (IL-6), which is known to be involved in RA onset and progression.

“SL1026 represents a new class of drug candidates for the treatment of diseases where interleukin-6 plays a central role, including cancer and other inflammatory diseases in addition to RA,” said Nebojsa Janjic, Chief Science Officer at SomaLogic. “These initial studies reinforce and extend the large potential of SOMAmer molecules as therapeutic agents.”

The researchers tested SL1026 in a total of 24 cynomolgus monkeys. Pharmacokinetic studies of the molecule in 12 monkeys across a range of doses established the dosing regimen for determining its effects on rheumatoid arthritis onset and progression in the other 12 animals. The complete results are available in the Nucleic Acid Therapeutics manuscript, which is available to all readers under an “open access” license.

“Our collaboration with Otsuka researchers over the past several years has been incredibly productive and gratifying,” said Byron Hewett, Chief Executive Officer at SomaLogic. “Its world-class expertise in drug development has made it a terrific partner for exploring the promise of our rapidly growing SOMAmer reagent library for addressing critical unmet need for novel therapeutics. We believe that the RA work is just the first of what will be many successful studies.”

Although there is no cure for RA, there are several treatment options for trying to manage the disease. Notable among these is the biological agent Actemra® (tocilizumab, Genentech), an antibody based drug that binds the IL-6 receptor protein, thus preventing IL-6 signaling through its receptor. Because it is based on nucleic acids rather than amino acids, SL1026 offers certain advantages over antibody-based drugs such as tocilizumab, including the lack of an immune response to the drug itself (as demonstrated in the published manuscript), and a more consistent chemical rather than biological synthesis method.

SomaLogic scientists can select SOMAmer reagents that specifically bind virtually any protein of interest, including those that are known to be important drug targets across a wide range of diseases and conditions.

*Hirota M. et al. (2015). Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. Nucleic Acid Therapeutics DOI: 10.1089/nat.2015.0567.


SomaLogic announces College of American Pathologists (CAP) accreditation of its CLIA laboratory

SomaLogic announces College of American Pathologists (CAP) accreditation of its CLIA laboratory

12/1/2015

SomaLogic, Inc. announced today that its SomaLogic Clinical Laboratory (CLIA laboratory) has been registered with the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988, and has received accreditation by the College of American Pathologists (CAP).

“The CAP accreditation of our CLIA laboratory is an important milestone on our way to applying our unique proteomic technology to the transformation of research and clinical diagnostics,” said Byron Hewett, CEO of SomaLogic. “Through our CLIA laboratory, we will be able to provide a growing range of cutting-edge tests and assays across many different diseases for the academic and pharmaceutical research communities and, soon, for clinical providers and their patients.”
SomaLogic’s upcoming new SOMAmer reagent-based test offerings from its CLIA laboratory are based on novel protein biomarker combinations, or “signatures,” which have been discovered through the application of the company’s SOMAscan assay to a wide array of many different diseases and conditions.

SomaLogic’s CMS Registration Number is 06D2093281, and its CAP Accreditation Number is 7223571. SomaLogic is in full compliance with all provisions (including the Privacy and Security Rules) of the Health Insurance Portability and Accountability Act of 1996.


SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

11/12/2015

SomaLogic was recognized as “Company of the Year” by the Colorado BioScience Association (CBSA) at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing “a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.” Chairman and Founder Larry Gold and CEO Byron Hewett accepted the award on behalf of the company.

CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers.
For more information, please visit the CBSA website.


SomaLogic launches new, larger commercial version of SOMAscan assay

SomaLogic launches new, larger commercial version of SOMAscan assay

9/23/2015

SomaLogic announced today that the latest version of its proprietary SOMAscan proteomics assay, which now measures 1,310 protein analytes, is commercially available to the life science research community. Called “SOMAscan Assay 1.3k,” this new version is replacing the current 1,129-measurement version, but without an increase in price.

“We are committed to increasing our already substantial lead in providing sensitive, accurate and highly multiplexed proteomics tools for novel biomarker discovery and development,” said Byron Hewett, Chief Executive Officer. “We plan to continue growing the number and diversity of proteins measured in our commercially available SOMAscan assay on a regular basis.”

Compared to other current proteomic technologies, SomaLogic’s SOMAscan assay offers its research users unprecedented power for novel protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. SOMAscan Assay 1.3k, which incorporates 1,310 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins from high to very low concentrations in small volumes of many different biological sample types.

Many of the nearly 200 new SOMAmer reagents added to the SOMAscan menu target proteins in inflammatory and oncology-related molecular pathways, a particular focus requested by current users of the assay. A list of the 1,310 proteins measured in SOMAscan Assay 1.3k may be downloaded from the SomaLogic website.

SOMAscan Assay 1.3k is primarily available as a service directly from SomaLogic, but access to the assay is also available at a growing number of select biomedical research centers. During the transition to the new SOMAscan version, the 1,129-analyte assay will remain available for a short time at a reduced rate.


SomaLogic announces deployment of SOMAscan™ assay to University of Houston and Sidra Medical and Research Center

SomaLogic announces deployment of SOMAscan™ assay to University of Houston and Sidra Medical and Research Center

9/9/2015

SomaLogic announced today that the University of Houston (Houston, TX) and Sidra Medical and Research Center (Doha, Qatar) are the latest academic centers to deploy SomaLogic’s proprietary SOMAscan assay to accelerate protein biomarker discovery and development across multiple life science research studies in their respective institutions.

Ena Wang, MD, Division Chief of Translational Medicine and Jean-Charles Gravel, PhD, Director of Deep Phenotyping Core facility will oversee the SOMAscan deployment at Sidra Medical and Research Center; and Chandra Mohan, MD, PhD, the Hugh Roy and Lillie Cranz Cullen Endowed Professor in Biomedical Engineering is directing the deployment at the University of Houston.

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates over 1,000 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

“We are delighted that the University of Houston and Sidra Medical Research Center, under the capable leadership of Drs. Mohan, Wang and Gravel respectively, have joined a growing number of high quality biomedical research centers and scientists using our SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “We believe that the continued expansion of access to our technology will help accelerate critical new discoveries in biology and medicine.”

Other sites where the SOMAscan assay has been deployed include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, the University of Colorado Denver, the University of Manitoba’s Centre for Proteomics and Systems Biology, and the Weill Cornell Medical College in Qatar. Additional SOMAscan assay sites will be announced in the next several months.